JP2024016024A5 - - Google Patents

Download PDF

Info

Publication number
JP2024016024A5
JP2024016024A5 JP2023172391A JP2023172391A JP2024016024A5 JP 2024016024 A5 JP2024016024 A5 JP 2024016024A5 JP 2023172391 A JP2023172391 A JP 2023172391A JP 2023172391 A JP2023172391 A JP 2023172391A JP 2024016024 A5 JP2024016024 A5 JP 2024016024A5
Authority
JP
Japan
Prior art keywords
chain variable
variable region
light chain
seq
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2023172391A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024016024A (ja
JP7827951B2 (ja
Filing date
Publication date
Priority claimed from JP2022547787A external-priority patent/JP7364315B2/ja
Application filed filed Critical
Publication of JP2024016024A publication Critical patent/JP2024016024A/ja
Publication of JP2024016024A5 publication Critical patent/JP2024016024A5/ja
Application granted granted Critical
Publication of JP7827951B2 publication Critical patent/JP7827951B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2023172391A 2020-03-27 2023-10-03 抗体結合Siglec15及びその使用 Active JP7827951B2 (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202063000566P 2020-03-27 2020-03-27
US63/000,566 2020-03-27
JP2022547787A JP7364315B2 (ja) 2020-03-27 2021-03-26 抗体結合Siglec15及びその使用
PCT/CN2021/083194 WO2021190622A1 (en) 2020-03-27 2021-03-26 Antibodies binding siglec15 and uses thereof

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2022547787A Division JP7364315B2 (ja) 2020-03-27 2021-03-26 抗体結合Siglec15及びその使用

Publications (3)

Publication Number Publication Date
JP2024016024A JP2024016024A (ja) 2024-02-06
JP2024016024A5 true JP2024016024A5 (enExample) 2024-04-04
JP7827951B2 JP7827951B2 (ja) 2026-03-11

Family

ID=77891322

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022547787A Active JP7364315B2 (ja) 2020-03-27 2021-03-26 抗体結合Siglec15及びその使用
JP2023172391A Active JP7827951B2 (ja) 2020-03-27 2023-10-03 抗体結合Siglec15及びその使用

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2022547787A Active JP7364315B2 (ja) 2020-03-27 2021-03-26 抗体結合Siglec15及びその使用

Country Status (12)

Country Link
US (2) US11739147B2 (enExample)
EP (1) EP4126938A4 (enExample)
JP (2) JP7364315B2 (enExample)
KR (1) KR102651263B1 (enExample)
CN (1) CN115348970B (enExample)
AU (2) AU2021240769B2 (enExample)
BR (1) BR112022019129A2 (enExample)
IL (1) IL296736B2 (enExample)
MX (1) MX2022011951A (enExample)
PH (1) PH12022552520A1 (enExample)
SA (1) SA522440646B1 (enExample)
WO (1) WO2021190622A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2021240769B2 (en) * 2020-03-27 2023-04-06 Biosion Inc. Antibodies binding Siglec15 and uses thereof
US20260070974A1 (en) * 2021-11-25 2026-03-12 Nona Biosciences (Suzhou) Co., Ltd. Anti-siglec-15 antibody and use thereof
CN114134183B (zh) * 2021-12-24 2022-12-06 广东南模生物科技有限公司 一种siglec15基因人源化动物模型的构建方法及应用
CN114807052A (zh) * 2022-06-07 2022-07-29 江苏亲科生物研究中心有限公司 Siglec15单克隆抗体及其制备方法和用途
CA3259231A1 (en) * 2022-06-13 2023-12-21 Shanghai Institute Of Biological Products Co., Ltd. ANTI-SIGLEC15 ANTIBODIES AND THEIR USES
WO2024040194A1 (en) 2022-08-17 2024-02-22 Capstan Therapeutics, Inc. Conditioning for in vivo immune cell engineering

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4604184B2 (ja) * 2005-07-12 2010-12-22 独立行政法人産業技術総合研究所 新規糖鎖認識蛋白質及びその遺伝子
US8168181B2 (en) 2006-02-13 2012-05-01 Alethia Biotherapeutics, Inc. Methods of impairing osteoclast differentiation using antibodies that bind siglec-15
KR20130066682A (ko) * 2010-10-05 2013-06-20 다이이찌 산쿄 가부시키가이샤 항체 표적 파골세포-관련 단백질 siglec-15
EP2753356B1 (en) 2011-09-09 2021-12-22 Medimmune Limited Anti-siglec-15 antibodies and uses thereof
CA2868965A1 (en) * 2012-03-30 2013-10-03 Daiichi Sankyo Company, Limited Anti-siglec-15 antibody
ES2723885T3 (es) * 2012-07-19 2019-09-03 Daiichi Sankyo Co Ltd Anticuerpos anti-Siglec-15
EP3157562A4 (en) * 2014-06-18 2017-12-20 Daiichi Sankyo Company, Limited Anti-siglec-15 antibodies for use in treatment of osteogenesis imperfecta
BR112018009361A8 (pt) * 2015-11-10 2019-02-26 Univ Yale composições e métodos para o tratamento de doenças autoimunes e de câncer
ES2982558T3 (es) * 2016-09-21 2024-10-16 Nextcure Inc Anticuerpos para Siglec-15 y métodos de uso de los mismos
CN108250296B (zh) * 2018-01-17 2020-07-07 长春金赛药业有限责任公司 全人源抗人pd-l1单克隆抗体及其应用
JP7156653B2 (ja) * 2018-08-30 2022-10-19 イノベイティブ セルラー セラピューティクス ホールディングス,エルティディ 固形腫瘍を治療するためのキメラ抗原受容体細胞
AU2021240769B2 (en) * 2020-03-27 2023-04-06 Biosion Inc. Antibodies binding Siglec15 and uses thereof

Similar Documents

Publication Publication Date Title
JP2024016024A5 (enExample)
RU2019116624A (ru) Новые анти_cd137 антитела и их применение
JP2020501531A5 (enExample)
JP2013502913A5 (enExample)
JP2014158469A5 (enExample)
JP2010504755A5 (enExample)
HRP20120701T1 (hr) Humana monoklonska protutijela protiv fukozil-gm1 i postupci za uporabu antifukozil-gm1
CA2523449A1 (en) Recombinant antibodies and fragments which recognize n glycolil gm3 ganglioside and its use in diagnosis and treatment of tumours
CN111278861A (zh) Pd-l1抗体、其抗原结合片段及医药用途
US20250034273A1 (en) Composition of multispecific antibodies targeting cadherin-17-expressing tumors and method of making and using thereof
JPWO2021139777A5 (enExample)
JP2020533965A5 (enExample)
JP2022521305A (ja) 抗pd-l1抗体及びその使用
JP2024020436A5 (enExample)
JP2018529672A5 (enExample)
JP2025130076A5 (enExample)
JPWO2022067262A5 (enExample)
JPWO2019217332A5 (enExample)
JPWO2021190622A5 (enExample)
JPWO2022256559A5 (enExample)
JP7808831B2 (ja) 抗cd26抗体とその応用
JP2026506070A (ja) 抗cntn4抗体及びその使用
JPWO2023098888A5 (enExample)
JPWO2022051591A5 (enExample)
JPWO2021068841A5 (enExample)